Binbin Xie

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (15)

• Data from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
  2023 DOI: 10.1158/1535-7163.c.6542092.v1
  +Save
• Data from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
  2023 DOI: 10.1158/1535-7163.c.6542092
  +Save
• Figure S1 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
  2023 DOI: 10.1158/1535-7163.22518733.v1
  +Save
• Figure S1 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
  2023 DOI: 10.1158/1535-7163.22518733
  +Save
• Figure S2 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
  2023 DOI: 10.1158/1535-7163.22518730.v1
  +Save
• Figure S2 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
  2023 DOI: 10.1158/1535-7163.22518730
  +Save
• Figure S3 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
  2023 DOI: 10.1158/1535-7163.22518727.v1
  +Save
• Figure S3 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
  2023 DOI: 10.1158/1535-7163.22518727
  +Save
• Figure S4 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
  2023 DOI: 10.1158/1535-7163.22518724.v1
  +Save
• Figure S4 from Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
  2023 DOI: 10.1158/1535-7163.22518724
  +Save